BACKGROUND: Converging evidence suggests that immune-mediated dysfunction plays an important role in the pathogenesis of frontotemporal dementia (FTD). Although genetic studies have shown that immune-associated loci are associated with increased FTD risk, a systematic investigation of genetic overlap between immune-mediated diseases and the spectrum of FTD-related disorders has not been performed. CONCLUSIONS: We show immune-mediated genetic enrichment specifically in FTD, particularly within the HLA region. Our genetic results suggest that for a subset of patients, immune dysfunction may contribute to FTD risk. These findings have potential implications for clinical trials targeting immune dysfunction in patients with FTD.
Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies / Broce, I., Karch, C.M., Wen, N., Fan, C.C., Wang, Y., Tan, C.H., Kouri, N., Ross, O.A., Höglinger, G.U., Muller, U., Hardy, J., Momeni, P., Hess, C.P., Dillon, W.P., Miller, Z.A., Bonham, L.W., Rabinovici, G.D., Rosen, H.J., Schellenberg, G.D., Franke, A., et al.. - In: PLOS MEDICINE. - ISSN 1549-1277. - ELETTRONICO. - 15:(2018), pp. e1002487-0. [10.1371/journal.pmed.1002487]
Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies
Nacmias, B;Sorbi, S;Bagnoli, S;Piaceri, I;
2018
Abstract
BACKGROUND: Converging evidence suggests that immune-mediated dysfunction plays an important role in the pathogenesis of frontotemporal dementia (FTD). Although genetic studies have shown that immune-associated loci are associated with increased FTD risk, a systematic investigation of genetic overlap between immune-mediated diseases and the spectrum of FTD-related disorders has not been performed. CONCLUSIONS: We show immune-mediated genetic enrichment specifically in FTD, particularly within the HLA region. Our genetic results suggest that for a subset of patients, immune dysfunction may contribute to FTD risk. These findings have potential implications for clinical trials targeting immune dysfunction in patients with FTD.| File | Dimensione | Formato | |
|---|---|---|---|
|
journal.pmed.1002487.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
4.02 MB
Formato
Adobe PDF
|
4.02 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



